Comprehensive Stock Comparison
Compare BlackRock Technology and Private Equity Term Trust (BTX) vs Royalty Pharma plc (RPRX) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth |  RPRX | 5.1% revenue growth vs BTX's -81.1% |
| Value | RPRX | Lower P/E (9.8x vs 38.9x) |
| Quality / Margins |  BTX | 87.7% net margin vs RPRX's 32.6% |
| Stability / Safety | RPRX | Beta 0.36 vs BTX's 1.16 |
| Dividends | BTX | 12.9% yield, 1-year raise streak, vs RPRX's 1.4% |
| Momentum (1Y) | RPRX | +43.1% vs BTX's +6.8% |
| Efficiency (ROA) | RPRX | 4.0% ROA vs BTX's 1.8%, ROIC 6.7% vs 1.4% |
Who Each Stock Is For
Income & stability
RPRXDividend streak 2 yrs, beta 0.36, yield 1.4%
Growth exposure
RPRXRev growth 5.1%, EPS growth -6.9%, 3Y rev CAGR 2.1%
Long-term compounding (10Y)
RPRX16.7% 10Y total return vs BTX's -45.5%
Sleep-well-at-night portfolio
RPRXLower volatility, beta 0.36, Low D/E 91.5%, current ratio 0.97x
Defensive / Recession hedge
RPRXBeta 0.36, yield 1.4%, current ratio 0.97x
Business Model
What each company does and how it makes money
BlackRock Technology and Private Equity Term Trust is a closed-end investment fund that pools investor capital to invest primarily in mid- and small-capitalization growth companies in the technology and healthcare sectors. It generates returns through capital appreciation and dividend income from its equity portfolio, with performance tied to the success of its underlying investments. The fund's key advantage is BlackRock's extensive research capabilities and access to innovative companies that traditional investors might overlook.
Royalty Pharma is a specialized investment firm that acquires royalty interests in approved and development-stage biopharmaceutical products. It generates revenue primarily from royalty payments on approximately 35 marketed therapies — with its largest assets including cystic fibrosis drug Trikafta and HIV treatment Biktarvy — which provide predictable cash flows. The company's competitive advantage lies in its deep expertise in valuing complex biopharmaceutical royalties and its extensive industry relationships that provide access to proprietary deal flow.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
RPRX 3BTX 2BTX3/3 metricsBTX3/5 metricsRPRX5/8 metricsRPRX6/6 metricsRPRX2/2 metricsRPRX leads in 3 of 6 categories (Profitability & Efficiency, Total Returns). BTX leads in 2 (Financial Metrics, Valuation Metrics). 1 tied.
Financial Metrics (TTM)
RPRX is the larger business by revenue, generating $2.3B annually — 57.7x BTX's $41M. BTX is the more profitable business, keeping 87.7% of every revenue dollar as net income compared to RPRX's 32.6%.
| Metric | BTXBlackRock Technol… | RPRXRoyalty Pharma plc |
|---|---|---|
| RevenueTrailing 12 months | $41M | $2.3B |
| EBITDAEarnings before interest/tax | — | $1.5B |
| Net IncomeAfter-tax profit | — | $765M |
| Free Cash FlowCash after capex | — | $2.4B |
| Gross MarginGross profit ÷ Revenue | +100.0% | +100.0% |
| Operating MarginEBIT ÷ Revenue | +87.7% | +65.2% |
| Net MarginNet income ÷ Revenue | +87.7% | +32.6% |
| FCF MarginFCF ÷ Revenue | +6.8% | +102.4% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +7.9% |
| EPS Growth (YoY)Latest quarter vs prior year | — | -44.8% |
Valuation Metrics
At 26.6x trailing earnings, RPRX trades at a 32% valuation discount to BTX's 38.9x P/E. On an enterprise value basis, BTX's 21.6x EV/EBITDA is more attractive than RPRX's 22.5x.
| Metric | BTXBlackRock Technol… | RPRXRoyalty Pharma plc |
|---|---|---|
| Market CapShares × price | $773M | $26.8B |
| Enterprise ValueMkt cap + debt − cash | $773M | $35.1B |
| Trailing P/EPrice ÷ TTM EPS | 38.94x | 26.65x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 9.75x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 21.64x | 22.51x |
| Price / SalesMarket cap ÷ Revenue | 18.99x | 11.26x |
| Price / BookPrice ÷ Book value/share | 0.80x | 2.74x |
| Price / FCFMarket cap ÷ FCF | 2.79x | 10.75x |
Profitability & Efficiency
RPRX delivers a 8.0% return on equity — every $100 of shareholder capital generates $8 in annual profit, vs $2 for BTX. On the Piotroski fundamental quality scale (0–9), RPRX scores 4/9 vs BTX's 3/9, reflecting mixed financial health.
| Metric | BTXBlackRock Technol… | RPRXRoyalty Pharma plc |
|---|---|---|
| ROE (TTM)Return on equity | +1.9% | +8.0% |
| ROA (TTM)Return on assets | +1.8% | +4.0% |
| ROICReturn on invested capital | +1.4% | +6.7% |
| ROCEReturn on capital employed | +1.8% | +8.7% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 4 |
| Debt / EquityFinancial leverage | — | 0.91x |
| Net DebtTotal debt minus cash | $0 | $8.3B |
| Cash & Equiv.Liquid assets | — | $619M |
| Total DebtShort + long-term debt | $0 | $9.0B |
| Interest CoverageEBIT ÷ Interest expense | 2313.25x | 5.66x |
Total Returns (with DRIP)
A $10,000 investment in RPRX five years ago would be worth $12,100 today (with dividends reinvested), compared to $5,453 for BTX. Over the past 12 months, RPRX leads with a +43.1% total return vs BTX's +6.8%. The 3-year compound annual growth rate (CAGR) favors RPRX at 12.5% vs BTX's 5.8% — a key indicator of consistent wealth creation.
| Metric | BTXBlackRock Technol… | RPRXRoyalty Pharma plc |
|---|---|---|
| YTD ReturnYear-to-date | +0.5% | +22.7% |
| 1-Year ReturnPast 12 months | +6.8% | +43.1% |
| 3-Year ReturnCumulative with dividends | +18.3% | +42.2% |
| 5-Year ReturnCumulative with dividends | -45.5% | +21.0% |
| 10-Year ReturnCumulative with dividends | -45.5% | +16.7% |
| CAGR (3Y)Annualised 3-year return | +5.8% | +12.5% |
Risk & Volatility
RPRX is the less volatile stock with a 0.36 beta — it tends to amplify market swings less than BTX's 1.16 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. RPRX currently trades 99.1% from its 52-week high vs BTX's 88.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | BTXBlackRock Technol… | RPRXRoyalty Pharma plc |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.16x | 0.36x |
| 52-Week HighHighest price in past year | $7.50 | $47.86 |
| 52-Week LowLowest price in past year | $5.10 | $29.66 |
| % of 52W HighCurrent price vs 52-week peak | +88.3% | +99.1% |
| RSI (14)Momentum oscillator 0–100 | 47.3 | 81.9 |
| Avg Volume (50D)Average daily shares traded | 908K | 3.5M |
Analyst Outlook
For income investors, BTX offers the higher dividend yield at 12.93% vs RPRX's 1.41%.
| Metric | BTXBlackRock Technol… | RPRXRoyalty Pharma plc |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $49.40 |
| # AnalystsCovering analysts | — | 11 |
| Dividend YieldAnnual dividend ÷ price | +12.9% | +1.4% |
| Dividend StreakConsecutive years of raises | 1 | 2 |
| Dividend / ShareAnnual DPS | $0.86 | $0.67 |
| Buyback YieldShare repurchases ÷ mkt cap | +12.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Mar 21 | Mar 26 | Change |
|---|---|---|---|
| BlackRock Technolog… (BTX) | 100 | 33.57 | -66.4% |
| Royalty Pharma plc (RPRX) | 100 | 110.37 | +10.4% |
Royalty Pharma plc (RPRX) returned +21% over 5 years vs BlackRock Technolog… (BTX)'s -45%. A $10,000 investment in RPRX 5 years ago would be worth $12,100 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2017 | 2025 | Change |
|---|---|---|---|
| BlackRock Technolog… (BTX) | $-640M | $41M | +106.4% |
| Royalty Pharma plc (RPRX) | $1.6B | $2.4B | +48.8% |
Royalty Pharma plc's revenue grew from $1.6B (2017) to $2.4B (2025) — a 5.1% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2017 | 2025 | Change |
|---|---|---|---|
| BlackRock Technolog… (BTX) | 100.1% | 87.7% | -12.4% |
| Royalty Pharma plc (RPRX) | 75.7% | 32.4% | -57.2% |
Royalty Pharma plc's net margin went from 76% (2017) to 32% (2025).
Chart 4P/E Ratio History — 6 Years
| Stock | 2020 | 2025 | Change |
|---|---|---|---|
| Royalty Pharma plc (RPRX) | 19.3 | 21.7 | +12.4% |
Royalty Pharma plc has traded in a 11x–404x P/E range over 6 years; current trailing P/E is ~27x.
Chart 5EPS Growth — 10 Years
| Stock | 2017 | 2025 | Change |
|---|---|---|---|
| BlackRock Technolog… (BTX) | -2.58 | 0.17 | +106.6% |
| Royalty Pharma plc (RPRX) | 1.99 | 1.78 | -10.7% |
Royalty Pharma plc's EPS grew from $1.99 (2017) to $1.78 (2025) — a -1% CAGR.
Chart 6Free Cash Flow — 5 Years
BlackRock Technology and Private Equity Term Trust generated $277M FCF in 2024 (+106% vs 2021). Royalty Pharma plc generated $2B FCF in 2025 (+23% vs 2021).
BTX vs RPRX: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is BTX or RPRX a better buy right now?
Royalty Pharma plc (RPRX) offers the better valuation at 26.6x trailing P/E (9.8x forward), making it the more compelling value choice. Analysts rate Royalty Pharma plc (RPRX) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — BTX or RPRX?
On trailing P/E, Royalty Pharma plc (RPRX) is the cheapest at 26.6x versus BlackRock Technology and Private Equity Term Trust at 38.9x.
03Which is the better long-term investment — BTX or RPRX?
Over the past 5 years, Royalty Pharma plc (RPRX) delivered a total return of +21.0%, compared to -45.5% for BlackRock Technology and Private Equity Term Trust (BTX). A $10,000 investment in RPRX five years ago would be worth approximately $12K today (assuming dividends reinvested). Over 10 years, the gap is even starker: RPRX returned +16.7% versus BTX's -45.5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — BTX or RPRX?
By beta (market sensitivity over 5 years), Royalty Pharma plc (RPRX) is the lower-risk stock at 0.36β versus BlackRock Technology and Private Equity Term Trust's 1.16β — meaning BTX is approximately 225% more volatile than RPRX relative to the S&P 500.
05Which has better profit margins — BTX or RPRX?
BlackRock Technology and Private Equity Term Trust (BTX) is the more profitable company, earning 87.7% net margin versus 32.4% for Royalty Pharma plc — meaning it keeps 87.7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BTX leads at 87.7% versus 65.6% for RPRX. At the gross margin level — before operating expenses — BTX leads at 100.0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — BTX or RPRX?
All stocks in this comparison pay dividends. BlackRock Technology and Private Equity Term Trust (BTX) offers the highest yield at 12.9%, versus 1.4% for Royalty Pharma plc (RPRX).
07Is BTX or RPRX better for a retirement portfolio?
For long-horizon retirement investors, Royalty Pharma plc (RPRX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.36), 1.4% yield). Both have compounded well over 10 years (RPRX: +16.7%, BTX: -45.5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between BTX and RPRX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. In terms of investment character: BTX is a small-cap income-oriented stock; RPRX is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.